Scarica l'app Stockscreener
805.43
0.82%
6.54
Pre-mercato:
805.63
0.20
+0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly (LLY) Awaits European Approval for Alzheimer's Drug | - GuruFocus
Eli Lilly and Company India launches ‘We Know Now’ obesity awareness campaign - MediaBrief
Eli Lilly's Trademark Suit Not 'Abuse Of Process' - Law360
INSERTING and REPLACING Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines - Business Wire
A New Obesity Contender From China Targeting Same Receptors As Eli Lilly's Blockbuster - Benzinga
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings? - The Globe and Mail
The 3 Things That Matter for Eli Lilly Now - The Motley Fool
Lilly confirms date and conference call for second-quarter 2025 financial results announcement - MarketScreener
Eli Lilly Q2 2025 Earnings Call: Key Date and Details Investors Should Know - Stock Titan
Lilly completes tender offer for Verve Therapeutics shares By Investing.com - Investing.com Nigeria
Lilly and Verve announce expiration of Verve tender offer | Eli Lilly and Company - Eli Lilly and Company
Lilly Secures 55.7% of Verve Shares in $10.50 Cash Plus CVR Deal, Closing Set for July 25 - Stock Titan
Eli Lilly targets golden goose with Mounjaro launch in Korea amidst competitionCHOSUNBIZ - Chosunbiz
Tariffs Weigh on Eli Lilly Stock (LLY) Ahead of Earnings - TipRanks
Eli Lilly, GE Vernova Surge Among Wednesday’s Market Cap Stock Movers - Investing.com Canada
Eli Lilly’s Phase 3 Breast Cancer Study: A Potential Game-Changer? - TipRanks
Eli Lilly’s LY3971297 Study: A Potential Game-Changer in Obesity and Hypertension Treatment - TipRanks
Eli Lilly’s Baricitinib Study: A Potential Game-Changer for Juvenile Arthritis - TipRanks
Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition - Insider Monkey
Jim Cramer on Eli Lilly: “It Needs Breakthroughs in New Areas” - Insider Monkey
Earnings Preview: What To Expect From Eli Lilly's Report - Barchart.com
Eli Lilly (LLY) Collaborates on Alzheimer's Diagnostic Test with CE Mark Approval | LLY Stock News - GuruFocus
Lilly to launch Mounjaro in Korea in August without reimbursement - koreabiomed.com
BMO Capital Pounds the Table on Eli Lilly Stock (LLY) Ahead of Earnings - TipRanks
BMO Capital reiterates Eli Lilly stock rating with $900 price target By Investing.com - Investing.com South Africa
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term - Yahoo Finance
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - The Motley Fool
Eli Lilly (LLY) at a Crossroads: Assessing the Pullback, Earnings Catalysts, and Long-Term Growth in Diabetes, Obesity, and Alzheimer's - AInvest
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo.co
LLY Stock Quote Price and Forecast - CNN
Eli Lilly’s Strategic Advantage in GLP-1RAs and Alzheimer’s Markets Fuels Buy Rating - TipRanks
Eli Lilly: Competition Melts Away (NYSE:LLY) - Seeking Alpha
Eli Lilly and Company (NYSE:LLY) Shares Could Be 38% Below Their Intrinsic Value Estimate - 富途牛牛
Bernstein Remains Bullish on Eli Lilly and Company (LLY) With an $1,100 PT - Insider Monkey
Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com
Why Eli Lilly (LLY) is Emerging as a Dividend Growth Leader in Pharma for 2025 - Insider Monkey
J.P. Morgan Sees Strong Q2 for Eli Lilly, Maintains Overweight Rating - Insider Monkey
Eli Lilly and Company - Lifespan Research Institute
Is Eli Lilly Stock A Buy On A Fresh Bout Of Alzheimer's News? - Investor's Business Daily
Eli Lilly’s Innovative Study on Bimagrumab and Tirzepatide: Market Implications - TipRanks
Eli Lilly’s New Study on LY4050784: A Potential Game-Changer in Cancer Treatment - TipRanks
Eli Lilly’s LUCENT 3 Study: A Promising Step for Ulcerative Colitis Treatment - TipRanks
Eli Lilly’s KRAS Inhibitor Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Eli Lilly’s Lepodisiran Study: A Step Forward in Liver Function Treatment - TipRanks
Eli Lilly’s Weight Management Study: A Potential Game-Changer in Obesity Treatment - TipRanks
Eli Lilly’s Promising Phase 1 Study on LY4101174: A Potential Game-Changer in Cancer Treatment - TipRanks
Eli Lilly’s New Cancer Study: A Potential Game-Changer? - TipRanks
Eli Lilly & Co: Analyst Bullish on Diabetes Segment and Oncology Franchise Amid Competitive Pressures. - AInvest
Eli Lilly & Co: Promising Growth Prospects and Strategic Positioning Amid Competitive Pressures - TipRanks
Eli Lilly's stock drops 3.08% to $765.51 on July 17, down 21.29% from 52-week high. - AInvest
Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs? - The Motley Fool
LLY Stock Price and Chart — NYSE:LLY - TradingView
Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers By Investing.com - Investing.com India
Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers - Investing.com
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today? - Yahoo Finance
Senators reveal how much Lilly, Pfizer paid telehealth companies - statnews.com
Eli Lilly Bets Big On Obesity And Diabetes Drugs - Finimize
Jim Cramer on Eli Lilly: “How Can You Leave This One Right Here?” - MSN
ELI LILLY AND COMPANY (LLY) - MSN
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound - CNBC
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Benzinga
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail
Health Canada Expands Eli Lilly's Omvoh Indication to Crohn's, Approves Citrate-Free Formula - MarketScreener
0.27%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):